Open-Angle Glaucoma / Ocular Hypertension

About The Study:

Sponsored by Allergan, the purpose of this multi-center study, called ATHENA, is to investigate the safety and effectiveness of Bimatoprost SR compared with selective laser trabeculoplasty (SLT) in glaucoma or ocular hypertension.

All participants will be randomized to one of two study groups:

- **Group A**—SLT in the primary eye and Bimatoprost SR in the fellow eye
- **Group B**—Bimatoprost SR in the primary eye and SLT in the fellow eye

Participants participating in this study will make up to 22 scheduled study visits and 7 phone calls over a period of 14 months. Each visit will last anywhere from 2-5 hours.

Key Inclusion Criteria:

- Age ≥ 18 years
- IOP not adequately managed with topical medication for reasons other than medication efficacy—due to intolerance or nonadherence
- IOP ≥ 22 and ≤ 34 mmHg
- BCVA of 20/50 or better in the study eye

Key Exclusion Criteria:

- History of previous laser trabeculoplasty
- History of traumatic cataract and/or angle recession
- Central corneal thickness of < 480 or > 620 micrometers
- History of peripheral iridotomy/iridectomy in the inferior 180° of the iris
- Any history of trabeculectomy or other types of glaucoma surgery
- History of moderate or worse (≥2+) bulbar conjunctival hyperermia due to prostaglandin, prostamide, or prostaglandin use

---

For Additional Information Or To Refer A Patient, Contact:

Principal Investigator: Bruce E. Prum, Jr., MD
Study Coordinators: Ashton Leone, MPH, CCRP at (434) 243-5737 or aml7q@virginia.edu
Tamika Mercer, COA at (434) 243-2852 or tmm2v@virginia.edu
Allison Weiderhold at (434) 243-2921 or alw5rm@virginia.edu

UVA Ophthalmology